Physician profile
James E Dickson
NPI 1568475002
$10,639.33
in general payments reported to CMS, 2019-2025
24 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $940 · 2021: $2,246 · 2022: $2,107 · 2023: $1,477 · 2024: $1,283 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,363 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,363.01 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,951.90 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,817.69 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,599.88 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $1,203.62 | 2019-2025 | Rexulti |
| Allergan, INC. | $803.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $675.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $597.43 | 2019-2022 | |
| Bausch Health US, LLC | $478.98 | 2021-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $465.87 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $236.57 | 2024-2025 | Sunosi, Auvelity |
| Vanda Pharmaceuticals INC. | $212.07 | 2019-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $165.84 | 2022 | |
| Supernus Pharmaceuticals, INC. | $83.96 | 2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $78.26 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $63.63 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $47.60 | 2020 | |
| Medline Industries Lp | $30.00 | 2025 | |
| Merck Sharp & Dohme LLC | $27.88 | 2021-2022 | |
| Shire North American Group INC | $19.14 | 2019 | |
| Irhythm Technologies, INC. | $18.44 | 2024 | Zio Xt Patch, Zio Monitor |
| Eisai INC. | $18.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.47 | 2025 | Cobenfy |
| Neuronetics, INC. | $15.07 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.48 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.